Summit Therapeutics (NASDAQ:SMMT - Get Free Report) posted its earnings results on Thursday. The company reported ($0.09) EPS for the quarter, topping the consensus estimate of ($0.10) by $0.01, Zacks reports.
Summit Therapeutics Stock Up 0.2 %
Shares of Summit Therapeutics stock traded up $0.04 during mid-day trading on Wednesday, reaching $24.24. 3,232,879 shares of the stock traded hands, compared to its average volume of 3,859,594. The stock has a market capitalization of $18.00 billion, a PE ratio of -86.58 and a beta of -0.94. The business has a 50-day moving average of $21.74 and a 200 day moving average of $20.37. Summit Therapeutics has a fifty-two week low of $2.10 and a fifty-two week high of $36.91.
Analysts Set New Price Targets
Several equities analysts have weighed in on the company. Summit Redstone set a $35.00 price objective on Summit Therapeutics in a report on Wednesday, March 26th. Evercore ISI began coverage on Summit Therapeutics in a report on Wednesday, March 12th. They set an "outperform" rating and a $30.00 price objective on the stock. Cantor Fitzgerald restated an "overweight" rating on shares of Summit Therapeutics in a research report on Wednesday, April 23rd. Truist Financial assumed coverage on shares of Summit Therapeutics in a research note on Wednesday, January 8th. They issued a "buy" rating and a $35.00 target price on the stock. Finally, StockNews.com cut Summit Therapeutics from a "hold" rating to a "sell" rating in a report on Monday. One investment analyst has rated the stock with a sell rating and ten have given a buy rating to the company's stock. According to MarketBeat, the company has a consensus rating of "Moderate Buy" and an average target price of $37.40.
Read Our Latest Stock Report on Summit Therapeutics
Summit Therapeutics Company Profile
(
Get Free Report)
Summit Therapeutics Inc, a biopharmaceutical company, focuses on discovery, development, and commercialization of patient, physician, caregiver, and societal friendly medicinal therapies in the United States, and the United Kingdom. The company's lead development candidate is Ivonescimab, a bispecific antibody for immunotherapy through blockade of PD-1 with the anti-angiogenesis; and anti-infectives portfolio includes SMT-738, a novel class of precision antibiotics for the treatment of multidrug resistant infections, which primarily includes carbapenem-resistant Enterobacteriaceae infections.
Featured Stories
Before you consider Summit Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Summit Therapeutics wasn't on the list.
While Summit Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Today, we are inviting you to take a free peek at our proprietary, exclusive, and up-to-the-minute list of 20 stocks that Wall Street's top analysts hate.
Many of these appear to have good fundamentals and might seem like okay investments, but something is wrong. Analysts smell something seriously rotten about these companies. These are true "Strong Sell" stocks.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
